Averin Capital

Averin Capital is a New York-based venture capital and company creation firm specializing in the convergence of healthcare and technology. Established in 2023 by David and Eric Berry, the firm focuses on four primary verticals: deep technology (synthetic biology and genomics), artificial intelligence, longevity, and data-driven care. Averin Capital differentiates itself through its founders' extensive experience in building and scaling over 30 life science companies, including several valued at over $1 billion. The firm actively manages a portfolio of innovative health-tech companies, such as Biolinq and Freenome, which focus on continuous monitoring and early cancer detection. In early 2026, the firm launched a $250 million SPAC, Averin Capital Acquisition Corp, to facilitate public market entries for high-growth healthcare innovators.